Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00671424 · ClinicalTrials.gov registry record · Phase 1
A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00671424 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 48 participants.
The verdict
NCT00671424, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
Many patients with type 2 diabetes also have conditions that are treated with diuretics. The patients may also be treated with GSK189075 for their diabetes. This study is planned to assess possible effects of administering GSK189075 in combination with two frequently used diuretics.
Interventions
- DRUG Furosemide
- DRUG Hydrochlorothiazide (HCTZ)
- DRUG Remogliflozin etabonate (GSK189075)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00671424
The ClinicalTrials.gov registry entry for NCT00671424 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Furosemide is the first listed.
NCT00671424 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00671424 about?
NCT00671424 is a clinical study titled "A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide". Many patients with type 2 diabetes also have conditions that are treated with diuretics. The patients may also be treated with GSK189075 for their diabetes. This study is planned to assess possible effects of administering GSK189075 in combination with two frequently used diuretics.
What is the current status of trial NCT00671424?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2008-03. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00671424?
The interventions under investigation include: Furosemide (DRUG), Hydrochlorothiazide (HCTZ) (DRUG), Remogliflozin etabonate (GSK189075) (DRUG).
Who is sponsoring clinical trial NCT00671424?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.